Ocugen, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, has entered into an agreement with Jubilant HollisterStier of Spokane, WA for manufacturing of vaccine candidate COVAXIN for the U.S. and Canadian markets.   “We are fully committed to bringing COVAXIN to the U.S. and Canadian markets because it has the potential to save lives by adding a weapon to the ...